

**A New Era of Technology in Bringing Digital Pills to the World.**

*JV'n Monika1, JV'n Khushi Pahuja2, JV'n Shefali Singh3*

Email : ydvmoni13@gmail.com, khushipahuja6548@gmail.com shefalikrity6548@gmail.com

*JV'n Ms. Shilpasree*, Assistant Professor

Faculty of Pharmaceutical Science, Jayoti Vidyapeeth Women's University, Jaipur

**Abstract :**

Digital pills (DP) are a modern drug-device era that let's in to combine traditional medications with a monitoring device to report statistics approximately medicinal drug observance as well as sufferers' physiological records without human intervention. The Digital medicine System (DMS), a drug-tool mixture advanced for patients with severe intellectual illness, collectively combines adherence dimension with pharmacologic action with the aid of putting an ingestible sensor in a tablet, allowing for records sharing amongst patients, Health Care Providers (HCPs), and caregivers over a cellular interface. Non-adherence to drug compromises the helpfulness of psychiatric treatments in victims with Serious Mental Illness (SMI). The aggregate of wearable generation with a "Digital Ingestion Tracking Program" (DITP) embedded within an ache tablet may additionally allow patients, caregivers as well as healthcare companies to song ingestion of tablets via the internet or a cellphone app. Digital observance generation might be promising patient-targeted strategies for tracking observance. In November 2017, the Food and Drug Administration (FDA) authorized a version of a second-technology antipsychotic, aripiprazole; embedded with a sensor (Abilify MyCite). The paper highlights the impact of DMS and affords precise assessment about it.

**Keyword :** Digital medicine system; Aripiprazole; Observance; Adherence; Food and Drug Administration; Major Depressive disorder; Serious Mental Illness; Digital Ingestion Tracking Program; Medication Event Monitoring System.

**1. Introduction :**

The Digital Medicine System (DMS) is a revolutionary drug-device combination developed for sufferers with critical mental contamination. This integrates adherence size talents as part of the drug formula through an embedded ingestible sensor [1]. Serious Mental Illness (SMI) is one of the leading reasons of long-term incapacity global. Major Depressive disorder (MDD), schizophrenia, and bipolar disease had been ranked 2nd, 11th, and 17th, respectively, at the list of global reasons of lengthy-term disability surveyed in 188 nations by using the worldwide Burden of disorder study 2013. SMI influences a huge share of the US population; in 2012, the anticipated occurrence of intellectual contamination and SMI among adults become 18. 5% and 4.2%, respectively, primarily based on the country wide Survey on Drug Use and fitness.

Pharmacologic remedy interventions lessen the severity of SMI and enhance affected person results [2]. numerous modalities currently available for direct or goal evaluation of adherence, along with tablet counts, Medication Event Monitoring System (MEMS) bottle caps, pharmacy top off facts, and




biological assays from bodily fluids have obstacles, and none offer an actual degree of medicine ingestion. therefore, the capacity to exactly and objectively verify medicine adherence in sufferers with SMI remains a big unmet want. A newly advanced Digital Medicine System (DMS) gives a revolutionary opportunity to objectively measure and document real affected person medicine adherence [3]. emerging digital technologies are one of the quickest growing sectors inside the healthcare enterprise and are beginning to reshape our attitude on how a few diseases may be managed [4]. Analytical electrochemistry is locating a huge range of packages within the biomedical discipline. for example, there had been traits in one of a kind bio and electrochemical sensors which includes: nitric oxide sensors, glucose sensors, DNA sensors, hydrogen sulphide sensors, oxygen sensors, superoxide sensors, immune sensors and so on. [5]. a new discipline of digital remedy slackly described as the field of drugs that uses digital equipment to promote the exercise of medicine to 1 this is excessive-definition and far extra individualized has emerged.

## **2. Technology used in Digital Medicines :**

Digital drug treatments intention to enhance pharmaceutical remedy by improving affected person adherence [6]. the use of phone-based facts streams with regards to intellectual health research is steadily gaining traction inside the subject [7]. The brand-new era is the use of a digital remedy system in which a drug is mixed with an ingestible sensor that can transmit a signal when the drug-device mixture is uncovered to gastric acid in the stomach to permit actual- time data approximately remedy ingestion. it is hoped that this can increase medication adherence and in flip effect in stepped forward health effects and be value-saving [8]. Digital medicinal drug structures have the capability to provide numerous blessings to patient care, inclusive of growing remedy adherence, supplying actual- time monitoring of drug use and extenuating dangers of overdose and abuse. The DSM is a private digital device (telephone) which wirelessly connects to the affected person's documentation and routinely uploads their remedy prescriptions [9]. Wi-fi device with electrochemical sensing techniques may be used as an alternative. The oral solid instruction for the digital medication includes a tablet, a wearable sensor patch, and an ingestible sensor that is one (mm)<sup>2</sup> in size. The sensor is lined with digestible metals which includes copper and magnesium. as soon as ingested and activated via gastric fluid, the sensor generates an indication that is perceived by using the patch. In comparison to their daily permitted amounts for human consumption of 0.3% (7.7 mg) and 0.003% (9.8 mg), respectively, the quantity of copper and magnesium that may be absorbed through the intestine from the ingestible sensor may be quite little. The wearable sensor patch is a frame-worn sensor of approximately 10 cm in length that detects and records the date and time of medication ingestion. It should to be implemented at the upper frame (torso), and it is able to be worn during maximum sports, which includes exercise and bathing. high degrees of interest and water may also purpose the patch to strip off, so the adhesive should be replaced weekly. A novel digital medicine System (DMS) has been evolved for sufferers with critical mental infection to objectively measure and report ingestion of aripiprazole, an extraordinary antipsychotic [10]. DMS acts as smart medicinal drug reminder; clever medication reminder gadget is designed for, however no longer limited to, helping antique people in beautiful them- selves in taking their medicines at the exact time and in the correct quantity [11]. gadget takes up the prescription information from the person together with the duration of the prescription, the names of the drugs, the duration they may be to be

taken and the amount of each remedy which is to be taken. in any case this fact has been entered, machine will remind the consumer on the prescribed time of which medicinal drug is to be taken in form of a cell notification and an entirely reminder. Process of the digital medicine system outlined in Figure 1.



*Figure 1: Process of digital medicinal system.*

### 3. Digital pills with smart reminders:

Digital pills come in the form of gelatin capsules that contain a digital radiofrequency emitter and the preferred medication. Whilst ingested, the radiofrequency emitter is activated through the chloride ion gradient in the belly to transmit a completely unique sign [12]. Before transmitting data via 1/3-technology (3G) mobile signaling to a cloud-based server compliant with the Health Information Technology for Economic and Clinical Health (HITECH) and the Health Insurance Portability and Accountability Act (HIPAA), a hip-worn receiver detects this signal. Digital capsules are keyed up by way of the precise chloride ion gradient inside the belly and, therefore, cannot be activated out of doors of the body. The device can report many simultaneous ingestion events since each digital tablet emits a distinct frequency. In the America, the meals and Drug management evaluates both capsules and clinical devices. Newly Food and Drug Administration (FDA) approved drug- tool combos consist of a smart insulin pen, a smart tablet, and a clever inhaler [13]. Digital tablets are revolutionary and simple to operate and passively degree adherence, decreasing the want for a person to engage with technology to transmit adherence records. despite the fact that the DSM era has been in most cases examined in individuals with bodily diseases the first digital medicine released on the market is an antipsychotic. On November 13, 2017 the Food and Drug Administration (FDA) authorized 'Abilify MyCite' as the first drug. With a digital ingestion tracking device [14]. This antipsychotic medicine is geared up with an ingestible sensor which communicates with a wearable patch, a telephone app, and a web portal. Abilify MyCite is a collection of several technological tools, including trackers, sensors, patches, apps, programming, phones, and the internet. It draws on Science and Technology Studies (STS) and new materialism to argue that ingestible sensors and other new prescription drugs are creating a data-driven subjectivity in the generation of digital intellectual health, which has the potential to transform intellectual health care. This time period refers to the inextricability of facts, its processing and production, and the formation of subjectivity. [15].

Aripiprazole is an extraordinary antipsychotic agent with an intrinsic dopamine agonist activity of 30%. Aripiprazole exerts supplementary partial agonist movement on five-HT<sub>1A</sub> receptors and has antagonist residences at 5-HT<sub>2A</sub> receptors. In 2012, the FDA approved the ingestible sensor and wearable sensor patch developed and marketed by Proteus Digital Health, Inc. Thru their joint project with Otsuka Pharmaceutical, they evolved the Abilify® (aripiprazole) digital medicinal drug that is the primary time a new drug application for a digital medication is common for revision by using the FDA. When the digital medicine Abilify (aripiprazole) is ingested, the sensor transmits a signal to the wearable sensor patch as it enters the stomach. This fact is recorded and relayed to patients on a cellular cellphone or other Bluetooth- enabled device and handiest with their consent to their physicians and/or their caregivers [16]. Abilify MyCite, is used in the remedy of schizophrenia, bipolar ailment, and despair. It combines aripiprazole with a digital sensor that, after being absorbed into the stomach, connects with a patch that the patient wears and automatically tracks the day, time, and dosage of the medication. [17].

#### 4. Dynamic market for digital pills :

- Growing prevalence of chronic disorders will drive the market: - The superiority of chronic issues consisting of diabetes and different cardiovascular sicknesses will enhance the adoption rate of digital capsules and further impact the market dynamics at some point of the forecast duration of 2022-2029.
- Patient compliance and medicine adherence will drive market growth during the forecast period.
  - a) Digital drugs are now more generally used to song remedy adherence or affected person compliance. they may also be used to collect statistics in scientific trials. therefore, this could flourish the increase charge of digital pills market.
  - b) Furthermore, decreased prices from wasted medicinal drugs will act as a primary element influencing the growth of digital drugs marketplace. Alongside this, favorable repayment policies and rising disposable income are the riding elements accelerating the increase of the digital tablets market [18]. Also, the upward push in the converting way of life and growing expenditure on healthcare infrastructure are the predominant marketplace drivers so one can similarly amplify the boom of digital tablets market. every other extensive factor in an effort to cushion the digital pills marketplace's growth price is the quicker healing times from extra adherence to treatment regimens and brief outcomes. Similarly, to this, growing improvement in endoscopy processes and monitoring the outcomes of sufferers regardless of region will cushion the growth price of digital capsules market.

#### 5. Challenges to Global Digital Pills Market:

- Market growth will be slowed by low adoption of digital pills.
  - a) However, due to some of troubles which include uncertain rules, lengthy-term negative outcomes, and the possibility of statistics privacy breach, digital tablet acceptance remains minimum. consequently, this may hinder the digital drugs marketplace's boom charge [19].
  - b) Then again, the lack of skilled specialists in healthcare sector will task the digital pills marketplace. moreover, high cost related to technological advancement and the shortage of attention

will act as restrain and further hinder the growth rate of marketplace at some point of the forecast duration of 2022-2029.

c) This digital drugs market document affords details of recent current trends, exchange rules, import-export analysis, production analysis, value chain optimization, marketplace share, impact of home and localized market gamers, analyses possibilities in terms of rising revenue pockets, modifications in market regulations, strategic market boom evaluation, market length, class market growths, software niches and dominance, product approvals, product launches, geographic expansions, technological improvements within the marketplace [20].

### 6. The current state of the global digital pills market:

The market for digital pills can be classified into different categories based on the product type, indication, distribution channel, diseases and end-user. Studying growth patterns in these segments can provide valuable market insights and a general overview to help informed decision-making for businesses looking to identify key market applications.

Product Type:

- a) Tablet
- b) Capsule
- c) Microchip Delivery Device

On the premise of product kind, digital drugs market place is segmented into pill, capsule and microchip delivery device.

#### Indication :

- a) Mental Disorders
- b) Infectious Diseases
- c) Cancer
- d) Others

Primarily based on indication, the digital capsules market is segmented into intellectual problems, cancer, infectious diseases and others [21].

#### Distribution Channel :

Based on distribution channel, the digital drugs market place is segmented into hospital pharmacies, retail pharmacies, strong point pharmacies and mail order pharmacies.

### 7. Alertness while using medication:

- Do not set up a new patch till instructed by the app.
- Do no longer take first DMS tablet till told through the app.
- Do not forestall or exchange medicine dosage based on statistics supplied via the DMs kit; consult health care issuer.

● Do not alter medicine unless told by way of prescribing health practitioner keep DMS components out of the attain of children.

● Do now not bite tablet.

● Do now not vicinity tablet in water.

● Do now not use the patch if allergic to adhesive [22].

### 8. Limitations:

#### ● Non adherence to medication is a common place concern :

Wrong remedy intake can cause suboptimal health for the affected person and, counter-intuitively, may also growth health-related fees [23].

#### ● Privacy :

Sufferers should provide consent so as for the information to be shared with fitness care vendors.

#### ● Cost :

This medicine is possibly fee extensively greater than the common model, making it inaccessible for many sufferers or limited to medical trials. Negative medication adherence produces massive downstream fitness care costs [24].

### 9. Medication compliance :

Adherence is a contested idea insofar as it's far imbued with meanings that enlarge beyond its strict [25]. Adherence is the degree to which a patient follows clinical advice, most typically with regard to taking medications, tracking of tablet consumption compliance and adherence can be optimized. Digital medicinal drug sensors improve the medicine adherence. Products that contain adherence tracking are already on the market and others are watching for FDA approval. For example, Rush university is the use of a compound pharmacy to combine current medicines with an ingestible sensor, evolved via Proteus digital fitness, Otsuka prescribed drugs' current FDA approval of a combination of the Proteus sensor with the drug Abilify (i.e., aripiprazole, which is presently FDA authorized for arrange of symptoms in the remedy of serious intellectual illnesses) [26].

### 10. Conclusion :

DMS units the idea for future research concerning both the capacity and concerns related to a wider use of digital pill and digitalization of traditional tablets. DMS represents the primary integrative digital fitness product evolved in psychiatry, in alignment with FDA HF steering. It gives sizable advantages now not viable with not unusual medical processes to address adherence issues. digital medicinal drug system ought to help transforming sustainable healthcare systems into sustainable ones. they may truly sign the new age of healthcare in destiny.

### Reference :

1. Abdul Minaam DS, Abd-El-Fattah M (2018) Smart drugs: Improving healthcare using Smart Pill Box for Medicine Reminder and Monitoring System. Future computing informs J 3: 28.
2. Akkermans J, de Lange AH, van der Heijden BIJM, Kooij DTAM, Jansen PGW, Dijkers JSE (2016) "What about time? Examining chronological and subjective age and their relation to work motivation". Career Dev Int 21: 419-439.

3. Chai PR, Carreiro S, Innes BJ, Rosen RK, O'Cleirigh C, et al. (2017) Digital pills to measure opioid ingestion patterns in emergency department patients with acute fracture pain: a pilot study. *J Med Internet Res* 19: e19.
4. Cosgrove L, Cristea IA, Shaughnessy AF, Mintzes B, Naudet F (2019) Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. *BMJ Evid Based Med* 24: 231-238.
5. Daar ES, Rosen MI, Wang Y, Siqueiros L, Shen J, et al. (2020) Real-time and wireless assessment of adherence to antiretroviral therapy with co-encapsulated ingestion sensor in HIV-infected patients: A pilot study. *Clin trans sci* 13: 189-94.
6. Dotolo D, Petros R, Berridge C (2018) A hard pill to swallow: ethical problems of digital medication. *Social work* 63: 370-372.
7. Egilman AC, Ross JS (2019) Digital medicine systems: an evergreening strategy or an advance in medication management? *BMJ Evid Based Med* 24: 203-204.
8. Fischer B, David's E, Gastpar M (2004) Aripiprazol Pharmakologie eines neuen atypischen Antipsychotikums. *Fortschr Neurol Psychiatry* 72: 497-502.
9. Flore J (2020) Ingestible sensors, data, and pharmaceuticals: Subjectivity in the era of digital mental health. *New Media Soc.* 2020: 1461444820931024.
10. Focsa S (2017) What can be done for access and reimbursement processes to reward innovation in digital "beyond the pill" solutions. *Value Health* 20: A708.
11. Frigerio M (2016) Getting approval for new therapeutic medical devices versus drugs: are the differences justified. *Eur Resp Rev* 25: 223-226.
12. Jongsma KR, Bredenoord AL, Lucivero F (2018) Digital medicine: an opportunity to revisit the role of bioethicists. *Am J Bioeth* 18: 69-70.
13. Klugman CM, Dunn LB, Schwartz J, Cohen IG (2018) The ethics of smart pills and self-acting devices: Autonomy, truth-telling, and trust at the dawn of digital medicine. *Am J Bioethics*. 18: 38-47.
14. Kopelowicz A, Baker RA, Zhao C, Brewer C, Lawson E, Peters Strickland T (2017) A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness. *Neuropsych Dis Treatment* 13: 2641.
15. Martani A, Geneviève LD, Poppe C, Casonato C, Wangmo T (2020) Digital pills: a scoping review of the empirical literature and analysis of the ethical aspects. *BMC med ethics* 21: 1-3.
16. Mc Caffrey C, Twomey K, Ogurtsov VI (2015) Development of a wireless swallowable capsule with potentiostatic electrochemical sensor for gastrointestinal track investigation. *Sensor Actuat B-Chem* 218: 8-15.
17. Mulder T, Jagesar RR, Klingenberg AM, Bonnici JP, Kas MJ (2018) New European privacy regulation: Assessing the impact for digital medicine innovations. *Eur Psych* 54: 57-58.
18. Peters-Strickland T, Hatch A, Adenwala A, Atkinson K, Bartfeld B (2018) Human factors evaluation of a novel digital medicine system in psychiatry. *Neuropsych Dis Treat* 14: 553.
19. Peters-Strickland T, Pestreich L, Hatch A, Rohatagi S, Baker RA, et al. (2016) Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. *Neuropsych Dis Treat* 12: 2587
20. Plowman RS, Peters-Strickland T, Savage GM (2018) Digital medicines: clinical review on the safety of tablets with sensors. *Expert Opin Drug Saf* 17: 849-852.
21. Swartz AK (2018) Smart pills for psychosis: the tricky ethical challenges of digital medicine for serious mental illness. *Am J Bioethics* 18: 65-67.
22. Vallejo's X, Wu C (2017) Digital medicine: innovative drug device combination as new measure of medication adherence. *J Pharm Tech* 33: 137-139.



23. Van Biesen W, Decruyenaere J, Sideri K, Cockbain J, Sterckx S (2021) Remote digital monitoring of medication intake: methodological, medical, ethical and legal reflections. *Acta Clin Belg* 76: 209-216.
24. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ (2012) Interventions to improve adherence to self-administered 2021 Vol.13 No.6:26 6 This article is available from: <http://www.archivesofmedicine.com/> Archives of Medicine ISSN 1989-5216 medications for chronic diseases in the United States: a systematic review. *Annals Int Med.* 157: 785-95.
25. Young MA, DiMartino L (2018) Trackable pill digital technology in PRM & pain: Hype or hope. *Ann Phys Rehabil Med* 61: e115.
26. Zijp TR, Mol PG, Touw DJ, van Boven JF (2019) Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine. *EClinical Medicine* 15: 3-4.